Display options
Cite
Kerner J, Liu J, Wang K, et al. Canadian cancer screening disparities: a recent historical perspective. Curr Oncol. 2015;22(2):156-63doi: 10.3747/co.22.2539.
Kerner, J., Liu, J., Wang, K., Fung, S., Landry, C., Lockwood, G., Zitzelsberger, L., & Mai, V. (2015). Canadian cancer screening disparities: a recent historical perspective. Current oncology (Toronto, Ont.), 22(2), 156-63. https://doi.org/10.3747/co.22.2539
Kerner, J, et al. "Canadian cancer screening disparities: a recent historical perspective." Current oncology (Toronto, Ont.) vol. 22,2 (2015): 156-63. doi: https://doi.org/10.3747/co.22.2539
Kerner J, Liu J, Wang K, Fung S, Landry C, Lockwood G, Zitzelsberger L, Mai V. Canadian cancer screening disparities: a recent historical perspective. Curr Oncol. 2015 Apr;22(2):156-63. doi: 10.3747/co.22.2539. PMID: 25908914; PMCID: PMC4399612.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2015 Apr;22(2):156-63. doi: 10.3747/co.22.2539.

Canadian cancer screening disparities: a recent historical perspective.

Current oncology (Toronto, Ont.)

J Kerner, J Liu, K Wang, S Fung, C Landry, G Lockwood, L Zitzelsberger, V Mai

Affiliations

  1. Canadian Partnership Against Cancer, Toronto, ON.

PMID: 25908914 PMCID: PMC4399612 DOI: 10.3747/co.22.2539

Abstract

Across Canada, introduction of the Pap test for cervical cancer screening, followed by mammography for breast cancer screening and, more recently, the fecal occult blood test for colorectal cancer screening, has contributed to a reduction in cancer mortality. However, another contribution of screening has been disparities in cancer mortality between certain populations. Here, we explore the disparities associated with breast and cervical cancer screening and preliminary data concerning disparities in colorectal cancer screening. Although some disparities in screening utilization have been successfully reduced over time (for example, mammography and Pap test screening in rural and remote populations), screening utilization data for other populations (for example, low-income groups) clearly indicate that disparities have existed and continue to exist across Canada. Organized screening programs in Canada have been able to successfully engage 80% of women for regular cervical cancer screening and 70% of women for regular mammography screening, but of the women who remain to be reached or engaged in regular screening, those with the least resources, those who are the most isolated, and those who are least culturally integrated into Canadian society as a whole are over-represented. Population differences are also observed for utilization of colorectal cancer screening services. The research literature on interventions to promote screening utilization provides some evidence about what can be done to increase participation in organized screening by vulnerable populations. Adaption and adoption of evidence-based screening promotion interventions can increase the utilization of available screening services by populations that have experienced the greatest burden of disease with the least access to screening services.

Keywords: Cancer screening; cancer screening disparities

References

  1. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2346-52 - PubMed
  2. Ethn Dis. 2010 Autumn;20(4):463-6 - PubMed
  3. MMWR Morb Mortal Wkly Rep. 2012 Jan 27;61(3):41-5 - PubMed
  4. Can Fam Physician. 2005 Sep;51:1224-8 - PubMed
  5. Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1790-8 - PubMed
  6. Health Educ Behav. 2008 Dec;35(6):806-20 - PubMed
  7. Oncol Nurs Forum. 2003 Jul-Aug;30(4):669-77 - PubMed
  8. J Gen Intern Med. 2014 Jan;29(1):41-9 - PubMed
  9. BMC Fam Pract. 2009 May 29;10:37 - PubMed
  10. Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):923-31 - PubMed
  11. J Natl Cancer Inst. 2006 Sep 6;98(17):1226-37 - PubMed
  12. Ann Intern Med. 2006 Apr 18;144(8):563-71 - PubMed
  13. J Public Health Manag Pract. 2008 Mar-Apr;14(2):193-8 - PubMed
  14. Eur J Radiol. 2013 Jun;82(6):e262-7 - PubMed
  15. Cancer. 2006 Sep 1;107(5):959-66 - PubMed
  16. BMC Cancer. 2014 Jul 10;14:505 - PubMed
  17. Public Health Rep. 1994 Jan-Feb;109(1):104-11 - PubMed
  18. Cancer Detect Prev. 2002;26(4):320-7 - PubMed
  19. J Gen Intern Med. 2009 Feb;24(2):211-7 - PubMed
  20. Health Educ Behav. 2004 Aug;31(4 Suppl):29S-44S - PubMed
  21. Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):453-9 - PubMed
  22. BMC Public Health. 2012 Jun 07;12:413 - PubMed
  23. Patient Educ Couns. 2010 Dec;81 Suppl:S6-14 - PubMed
  24. Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):45-52 - PubMed
  25. J Gen Intern Med. 2011 Feb;26(2):123-9 - PubMed
  26. J Immigr Health. 2002 Jul;4(3):147-57 - PubMed
  27. BMJ Open. 2011 Feb 26;1(1):e000030 - PubMed
  28. J Rural Health. 1996 Spring;12(2):120-9 - PubMed
  29. Am J Public Health. 2007 Sep;97(9):1693-700 - PubMed
  30. Gastrointest Endosc. 2012 Mar;75(3):474-80 - PubMed
  31. Eur J Cancer. 2014 Nov;50(17):3029-38 - PubMed
  32. Health Educ Behav. 2008 Dec;35(6):749-62 - PubMed
  33. Am J Prev Med. 2000 Apr;18(3):199-207 - PubMed
  34. Am Fam Physician. 2013 Feb 15;87(4):274-8 - PubMed
  35. J Cancer Educ. 2010 Sep;25(3):405-12 - PubMed
  36. Prev Med. 1998 Nov-Dec;27(6):862-70 - PubMed
  37. Health Educ Behav. 2011 Oct;38(5):452-61 - PubMed

Publication Types